Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
about
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in miceInduction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirusThe Global HIV/AIDS Vaccine Enterprise: scientific strategic planPEGylated Adenoviruses: From Mice to MonkeysPrime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.Circumventing antivector immunity: potential use of nonhuman adenoviral vectorsSynthetic DNA vaccine strategies against persistent viral infectionsPre-existing vector immunity does not prevent replication deficient adenovirus from inducing efficient CD8 T-cell memory and recall responses4-1BBL enhances CD8+ T cell responses induced by vectored vaccines in mice but fails to improve immunogenicity in rhesus macaquesA novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.An Immunogenic and Protective Alphavirus Replicon Particle-Based Dengue Vaccine Overcomes Maternal Antibody Interference in Weanling MiceIncreased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA VaccineImproved Efficacy of a Gene Optimised Adenovirus-based Vaccine for Venezuelan Equine Encephalitis VirusRegulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbetaAd35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus speciesTransgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesProduction of adenovirus vectors and their use as a delivery system for influenza vaccines.Development of Vaccines for Chikungunya Fever.Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunityNon-classical natural killer T cells modulate plasmid DNA vaccine antigen expression and vaccine-elicited immune responses by MCP-1 secretion after interaction with a beta2-microglobulin-independent CD1d.Adenoviral vector immunity: its implications and circumvention strategies.Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses.HIV-1 vaccine development after STEP.The influence of innate and pre-existing immunity on adenovirus therapyHer2-specific multivalent adapters confer designed tropism to adenovirus for gene targetingMucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.Towards broad protection against Ebolaviruses.Host range, prevalence, and genetic diversity of adenoviruses in batsReplication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primatesSynergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.Structure-based programming of lymph-node targeting in molecular vaccines.Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaquesAdenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunityReplicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.
P2860
Q21092172-FC633FC2-802A-40F9-9BD8-C4DD547B5E7BQ21092179-F8E36C01-B89E-4260-8A90-3F792DC47867Q21563445-9B3B4B45-4A43-4DA0-91BC-84961BFC1D1BQ24635276-3B859A9A-5F8A-49D4-A1DE-39A2A068388BQ24813328-9878356B-2EFA-4C9B-8C76-AAD57D995684Q26995655-ED948EE8-57EF-4CDC-B355-3124B89EE91BQ27016078-4A6E27E2-222D-4C51-99D3-D21A5066752EQ27304910-B88CA460-6D7D-4C52-9B97-5FC2FB6DC13AQ27314155-7E656451-12C5-409F-B23C-40C296F15B4CQ27472927-8770FB57-87E9-4D2E-9A29-FF4FAE9D00E9Q27481478-80026467-8548-406D-8965-96164D4FF4A6Q27485003-D6C4152A-6E01-4A2A-84BC-84105938E0C7Q27489413-89C6B6A6-8F82-4CB8-AC8A-792498EDF363Q28475223-D4C2F54A-8512-4B7B-B8C0-BCDE38BE7C86Q28485505-8940C534-9A6B-4D44-A740-9FDB9AAD46C9Q28743564-17B4F8FC-C7D4-497F-8D61-C640BCEDA226Q28744149-CC6AF856-E340-4D46-9395-0B5201603E19Q28749120-31ECC456-9E4D-4630-964A-79D7A4D6B546Q30226988-1725E0B2-D0E3-4D04-9276-4CE1CF4167E6Q30240191-81AD4766-B446-4B2F-93EF-105088D444F7Q33262597-71B31927-EF33-4E1C-93D2-82186B156A75Q33327757-94E7C616-8064-4652-9AA0-26E2F32977A3Q33553298-D3DD3305-13C2-49E9-A252-2BC9AB2CE322Q33565630-9FB19F24-7560-45FD-B880-CEDC89D8F6A8Q33630150-9643CDDF-41D8-4F61-B194-9EDF34B27569Q33642318-AC3A7612-636D-4F4A-9E29-FC3A62846218Q33655401-FCF2F9E5-C0B4-4DB2-9147-E1B5F0A11043Q33740415-80C3CC3E-E9FA-467F-8516-DFC0DCA0E626Q33743800-055CBDAB-5F2E-4796-AF7A-9ABA095493DEQ33745567-63492AAE-E9D6-4006-8B91-ECE2CB2BC7BEQ33769343-08B2D0C1-0279-48DA-AF28-5A336762CBB7Q33780685-7EE1026E-13C8-4871-9086-318A2B1CD15BQ33798772-F4C29320-07C8-4243-AB85-D3412DB6E377Q33800766-031800B5-6654-4189-A74F-FF1874909077Q33843258-55891237-29E2-428F-82A5-270204B658B4Q33848838-E9B7F144-5FCE-4C82-9D4A-DC9D9B2022EFQ33877458-FB80BA31-ABC1-42DC-8D6C-0E913EDAF1C0Q33896435-9969C4A1-01AF-4774-837C-8BF44675032AQ33908767-94B81448-01A9-4EC5-A925-F0367FD2CE07Q33911986-676EE6ED-3895-4273-9FFC-8D9F74837486
P2860
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@en
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@nl
type
label
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@en
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@nl
prefLabel
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@en
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@nl
P2093
P50
P1476
Immunogenicity of recombinant ...... re-existing anti-Ad5 immunity.
@en
P2093
Birgit Korioth-Schmitz
Dan H Barouch
Darci A Gorgone
Dennis L Panicali
Diana M Truitt
Jerome H H V Custers
Maria G Pau
Menzo J E Havenga
Michael G Kishko
Michael H Newberg
P304
P356
10.4049/JIMMUNOL.172.10.6290
P407
P577
2004-05-01T00:00:00Z